Trials / Unknown
UnknownNCT05123352
Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies
Investigation of the Gut Microbiota Evaluated by Metagenomic Next-Generation Sequencing (mNGS) in Acute Myeloid Leukemia Receiving Standard Intensive Chemotherapy or Bcl-2 Inhibitor-based Targeted Induction Therapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
In this observational single-center cohort study, metagenomic Next-Generation Sequencing (mNGS) will be used to investigate the features and changes of gut microbiota in acute myeloid leukemia (AML) patients during the treatment of two different induction therapy regimens \[standard intensive chemotherapy (7+3) or bcl-2 inhibitor-based targeted therapy\].
Detailed description
Infections remain one of the major complications during induction therapy of acute myelocytic leukemia (AML). Previous studies have shown that the variation of gut microbiota was an effective predictor for infection development of AML during induction therapy. A growing number of patients with AML received bcl-2 inhibitor-based targeted induction therapy. The investigators assume that there are different effects of bcl-2 inhibitor-based induction therapy on gut microbiota compared with standard intensive chemotherapy (7+3 regimen). Metagenomic Next-Generation Sequencing (mNGS) will be used to perform the investigation of gut microbiota in AML receiving two different induction therapies. And the relationships of gut microbiota with infection complication will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | collection of biological samples and clinical data | blood and feces samples |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2022-06-01
- Completion
- 2022-11-01
- First posted
- 2021-11-17
- Last updated
- 2021-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05123352. Inclusion in this directory is not an endorsement.